Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $156,941.40 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Shalini Sharp sold 1,106 shares of the firm’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $141.90, for a total value of $156,941.40. Following the completion of the sale, the director now directly owns 994 shares in the company, valued at $141,048.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neurocrine Biosciences Trading Up 0.8 %

NASDAQ:NBIX opened at $140.51 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $89.04 and a 1 year high of $148.37. The firm has a 50 day moving average of $138.66 and a 200-day moving average of $131.70. The stock has a market capitalization of $14.14 billion, a P/E ratio of 38.71 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The company had revenue of $515.30 million during the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post 4.17 EPS for the current fiscal year.

Institutional Trading of Neurocrine Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. FCF Advisors LLC acquired a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $1,157,000. abrdn plc grew its holdings in Neurocrine Biosciences by 2,503.0% during the 4th quarter. abrdn plc now owns 83,633 shares of the company’s stock worth $11,019,000 after acquiring an additional 80,420 shares during the period. Redhawk Wealth Advisors Inc. acquired a new stake in Neurocrine Biosciences during the 4th quarter worth $1,245,000. HealthInvest Partners AB acquired a new stake in Neurocrine Biosciences during the 4th quarter worth $1,662,000. Finally, Roman Butler Fullerton & Co. acquired a new stake in Neurocrine Biosciences during the 4th quarter worth $1,256,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the topic of several research analyst reports. Guggenheim raised their price target on Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Mizuho increased their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. Barclays increased their target price on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Wednesday, May 1st. Finally, StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $148.96.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.